FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:492-507 July 31, 2008 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

Malignant gliomas account for approximately 70% of the 22,500 new cases of malignant primary brain tumors that are diagnosed in adults in the United States each year.^1,2,3 Although relatively uncommon, malignant gliomas are associated with disproportionately high morbidity and mortality. Despite optimal treatment, the median survival is only 12 to 15 months for patients with glioblastomas and 2 to 5 years for patients with anaplastic gliomas. Recently, there have been important advances in our understanding of the molecular pathogenesis of malignant gliomas and progress in treating them. This review summarizes the diagnosis and management of these tumors in adults and . . . [Full Text of this Article]

Epidemiologic Features

Pathological Features

Molecular Pathogenesis

Deregulated Growth Factor Signaling

Role of Stem Cells in Pathogenesis and Resistance to Therapy

Diagnosis

Clinical Presentation

Imaging

Treatment

General Medical Management

Specific Therapy for Newly Diagnosed Malignant Gliomas

Therapy for Anaplastic Gliomas

Therapy for Recurrent Malignant Gliomas

Investigational Therapies

Targeted Molecular Therapies

Antiangiogenic Agents

Other Therapies

Prognostic Factors

Summary

Source Information

From the Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital; and the Center for Neuro-Oncology, Dana–Farber Cancer Institute — both in Boston.

Address reprint requests to Dr. Wen at the Center for Neuro-Oncology, Dana–Farber/Brigham and Women's Cancer Center, SW430D, 44 Binney St., Boston, MA 02115, or at pwen@partners.org.

Related Letters:

Malignant Gliomas in Adults
Meyer M. A., Wen P. Y., Kesari S.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:1850, Oct 23, 2008. Correspondence

This article has been cited by other articles:

• Golding, S. E., Rosenberg, E., Valerie, N., Hussaini, I., Frigerio, M., Cockcroft, X. F., Chong, W. Y., Hummersone, M., Rigoreau, L., Menear, K. A., O'Connor, M. J., Povirk, L. F., van Meter, T., Valerie, K. (2009). Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Molecular Cancer Therapeutics 8: 2894-2902 [Abstract] [Full Text]  
• Kapitonov, D., Allegood, J. C., Mitchell, C., Hait, N. C., Almenara, J. A., Adams, J. K., Zipkin, R. E., Dent, P., Kordula, T., Milstien, S., Spiegel, S. (2009). Targeting Sphingosine Kinase 1 Inhibits Akt Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts. Cancer Res. 69: 6915-6923 [Abstract] [Full Text]  
• Burgoyne, A. M., Phillips-Mason, P. J., Burden-Gulley, S. M., Robinson, S., Sloan, A. E., Miller, R. H., Brady-Kalnay, S. M. (2009). Proteolytic Cleavage of Protein Tyrosine Phosphatase {micro} Regulates Glioblastoma Cell Migration. Cancer Res. 69: 6960-6968 [Abstract] [Full Text]  
• Bredel, M., Scholtens, D. M., Harsh, G. R., Bredel, C., Chandler, J. P., Renfrow, J. J., Yadav, A. K., Vogel, H., Scheck, A. C., Tibshirani, R., Sikic, B. I. (2009). A Network Model of a Cooperative Genetic Landscape in Brain Tumors. JAMA 302: 261-275 [Abstract] [Full Text]  
• Wang, S., Zhou, Q., Gallo, J. M. (2009). Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Molecular Cancer Therapeutics 8: 1438-1447 [Abstract] [Full Text]  
• Stupp, R., Roila, F., On behalf of the ESMO Guidelines Working Group, (2009). Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv126-iv128 [Full Text]  
• Wakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T. Jr., Zaupa, C., Aghi, M., Kuroda, T., Stemmer-Rachamimov, A., Shah, K., Liu, T.-C., Jeyaretna, D. S., Debasitis, J., Pruszak, J., Martuza, R. L., Rabkin, S. D. (2009). Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. Cancer Res. 69: 3472-3481 [Abstract] [Full Text]  
• Griffero, F., Daga, A., Marubbi, D., Capra, M. C., Melotti, A., Pattarozzi, A., Gatti, M., Bajetto, A., Porcile, C., Barbieri, F., Favoni, R. E., Lo Casto, M., Zona, G., Spaziante, R., Florio, T., Corte, G. (2009). Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors. J. Biol. Chem. 284: 7138-7148 [Abstract] [Full Text]  
• Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K. W., Velculescu, V. E., Vogelstein, B., Bigner, D. D. (2009). IDH1 and IDH2 Mutations in Gliomas. NEJM 360: 765-773 [Abstract] [Full Text]  
• Wen, P. Y., Norden, A. D., Drappatz, J. (2009). Antiangiogenic Therapies for Malignant Gliomas. Am Soc Clin Oncol Ed Book 2009: 113-117 [Abstract] [Full Text]  
• Meyer, M. A., Wen, P. Y., Kesari, S. (2008). Malignant Gliomas in Adults. NEJM 359: 1850-1850 [Full Text]